Relapsed/Refractory Acute Myeloid Leukemia (AML)

Explore clinical trials studying Relapsed/Refractory Acute Myeloid Leukemia (AML). Study availability and eligibility vary by location and protocol.

7 public trials 4 recruiting studies

Refine in advanced search Browse all conditions

Relapsed/Refractory Acute Myeloid Leukemia (AML) trial results

Recruiting

Individualized AML Treatment

NCT07613385

Conditions: Hematologic Diseases, Hemic and Lymphatic Diseases, Leukemia, +5 more
Locations: City of Hope Medical Center Duarte, California, United States

View Trial Details

Recruiting

CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

NCT05143996

Conditions: Bone Marrow Diseases, Hematologic Diseases, Hemic and Lymphatic Diseases, +8 more
Locations: University of Alabama O'Neal Cancer Center Birmingham, Alabama, United States

UCLA Los Angeles, California, United States

University of Miami Health System Miami, Florida, United States

Moffitt Cancer Center Tampa, Florida, United States

View Trial Details

Recruiting

Thiotepa Combined With Busulfan and Fludarabine Conditioning Regimen for Haploidentical Hematopoietic Stem Cell Transplantation in Elderly Patients With High-Risk Acute Myeloid Leukemia

NCT06869265

Conditions: Acute Myeloid Leukemia (AML), Hematologic Diseases, Hemic and Lymphatic Diseases, +7 more
Locations: Peking University People's Hospital Beijing, Beijing Municipality, China

View Trial Details

Recruiting

A Phase 1 Clinical Trail of NTQ2494 Tablets in Patients With Advanced Hematological Malignancies

NCT06049667

Conditions: Hematologic Diseases, Hemic and Lymphatic Diseases, Leukemia, +5 more
Locations: Hematology Hospital of the Chinese Academy of Medical Sciences Tianjin, Tianjin Municipality, China

View Trial Details

Not Yet Recruiting

A Clinical Study to Investigate the Safety and Efficacy of Off-the-Shelf iNKT Cell Injection Targeting CD33/CD70 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia

NCT07676006

Conditions: Hematologic Diseases, Hemic and Lymphatic Diseases, Leukemia, +5 more
Locations: Shenzhen People's Hospital Shenzhen, Guangdong, China

View Trial Details

Not Yet Recruiting

Genetic Ablation of CD33 in HSC to Broaden the Therapeutic Index of CD33-directed Immunotherapy in Patients with AML

NCT05662904

Conditions: Hematologic Diseases, Hemic and Lymphatic Diseases, Leukemia, +5 more
Locations: University Hospital Dresden, Department of Medicine I Dresden, Germany

University Hospital Heidelberg, Internal Medicine V Heidelberg, Germany

View Trial Details

Completed

Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML

NCT02626338

Conditions: Hematologic Diseases, Hemic and Lymphatic Diseases, Leukemia, +5 more
Locations: University of Arkansas Little Rock, Arkansas, United States

City of Hope Medical Center Duarte, California, United States

University of Texas Southwestern Medical Center Dallas, Texas, United States

Houston Methodist Houston, Texas, United States

View Trial Details

Relapsed/Refractory Acute Myeloid Leukemia (AML)

Relapsed/Refractory Acute Myeloid Leukemia (AML) trial results

Individualized AML Treatment

CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Thiotepa Combined With Busulfan and Fludarabine Conditioning Regimen for Haploidentical Hematopoietic Stem Cell Transplantation in Elderly Patients With High-Risk Acute Myeloid Leukemia

A Phase 1 Clinical Trail of NTQ2494 Tablets in Patients With Advanced Hematological Malignancies

A Clinical Study to Investigate the Safety and Efficacy of Off-the-Shelf iNKT Cell Injection Targeting CD33/CD70 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia

Genetic Ablation of CD33 in HSC to Broaden the Therapeutic Index of CD33-directed Immunotherapy in Patients with AML

Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML

Related conditions